ca19-9 as a potential target for radiolabeled antibody-based positron emission tomography of pancreas cancerca19-9作为一个潜在的目标胰腺癌症的放射性标记的抗体类正电子发射断层扫描.pdfVIP

Hindawi Publishing Corporation International Journal of Molecular Imaging Volume 2011, Article ID 834515, 9 pages doi:10.1155/2011/834515 Research Article CA19-9 as a Potential Target for Radiolabeled Antibody-Based Positron Emission Tomography of Pancreas Cancer Mark D. Girgis,1, 2 Tove Olafsen,3 Vania Kenanova,3 Katelyn E. McCabe,3 Anna M. Wu,3 and James S. Tomlinson1, 2 1 Department of Surgery, UCLA, 10833 LeConte Avenue, Rm 54-140, Los Angeles, CA 90095, USA 2 Department of Surgery, Veterans Aff airs Greater Los Angeles, Health Care Center, Los Angeles, CA 90073, USA 3 Department of Molecular and Medical Pharmacology, Crump Institute for Molecular Imaging, Los Angeles, CA 90095, USA Correspondence should be addressed to James S. Tomlinson, jtomlinson@ Received 5 May 2011; Accepted 3 July 2011 Academic Editor: Ronald L. Van Heertum Copyright © 2011 Mark D. Girgis et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Introduction. Sensitive and specific imaging of pancreas cancer are necessary for accurate diagnosis, staging, and treatment. The vast majority of pancreas cancers express the carbohydrate tumor antigen CA19-9. The goal of this study was to determine the potential to target CA19-9 with a radiolabeled anti-CA19-9 antibody for imaging pancreas cancer. Methods. CA19-9 was quantified using flow cytometry on human pancreas cancer cell lines. An intact murine anti-CA19-9 monoclonal antibody was labeled with a positron emitting radionuclide (Iodine-124) and injected into mice harboring antigen positive and negative xenografts. MicroPET/CT were performed at successive time intervals (72 ho